SF3B1 and myelodysplastic syndrome: In the previous fourth edition of the WHO, MDS with ring sideroblasts (MDS-RS) was a distinct diagnostic entity requiring at least 5% ring sideroblasts in the presence of an SF3B1 mutation or >15% ring sideroblasts when SF3B1 is unmutated.